Intervertebral Disc Disease
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SeikagakuCondoliase
SeikagakuCondoliase
Spine BioPharmaNuCel with Autograft
Clinical Trials (3)
Total enrollment: 1,453 patients across 3 trials
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Start: Mar 2015Est. completion: Feb 20181,011 patients
Phase 3Completed
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Start: Sep 2013Est. completion: Aug 2017385 patients
Phase 3Completed
Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine
Start: Dec 2013Est. completion: Aug 201957 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.